Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management
INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ('SiteOne'), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
'The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive,' said Mark Mintun, Lilly group vice president Neuroscience Research and Development. 'Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies. Innovation in pain management is critical to address the unmet needs of millions of patients around the world.'
Under the terms of the agreement, Lilly will acquire SiteOne and SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.
'At SiteOne, we've spent more than a decade advancing a vision to deliver safer, more effective, non-opioid therapies for patients suffering from pain and other sensory hyperexcitability disorders,' said John Mulcahy, Ph.D., chief executive officer and cofounder of SiteOne Therapeutics. 'Lilly shares our deep commitment to scientific rigor, innovation, and patient-centered drug development. We believe their global capabilities and neuroscience leadership will accelerate our efforts to realize the full potential of STC-004 and our broader platform. This acquisition reflects the expertise and dedication of the SiteOne team and marks an exciting new chapter in our mission to transform pain treatment.'
The transaction is subject to customary closing conditions. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.
For Lilly, J.P. Morgan Securities LLC is acting as exclusive financial advisor and Jones Day is acting as legal counsel. For SiteOne, Centerview Partners LLC is acting as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP and Cooley LLP are acting as legal counsel.
About SiteOne Therapeutics
SiteOne Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting Nav1.7, Nav1.8, and other ion channels to treat pain, cough and other conditions involving hyperexcitability of the peripheral nervous system. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids. The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain. For more information, visit www.siteonetherapeutics.com.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of SiteOne and SiteOne's product candidates for treating pain, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
View original content to download multimedia: https://www.prnewswire.com/news-releases/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics-302465735.html
SOURCE Eli Lilly and Company
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Analysts assess the potential impact of Trump's surprise 50% steel tariffs
-- U.S. President Donald Trump unexpectedly announced on Friday that steel and aluminum tariffs will double to 50%. The move, set to come into effect on June 4, was unveiled during a campaign rally in Pennsylvania. It was later confirmed on TruthSocial and comes amid broader debates around U.S. industrial policy and foreign investment. Analysts are now evaluating the implications of this surprise decision, with most agreeing that the immediate domestic effects may be less severe than the broader geopolitical risks. JPMorgan's Tatsuya Maruyama said the direct impact on major Japanese steelmakers such as Nippon Steel Corp (TYO:5401), JFE Holdings, Inc. (TYO:5411), and Kobe Steel, Ltd. (TYO:5406) is expected to be limited, given that 'the U.S. accounts for about 4% of Japan's steel exports.' Maruyama pointed out in a Monday note that Nippon Steel and JFE export only about 1% of their total shipments to the U.S., while Kobe Steel exports about 3%. Still, he warned that 'rising global protectionism' is a growing concern, noting that a wave of anti-dumping measures and safeguards in regions like South Korea, the EU, and India could further strain global trade dynamics. 'If such countermeasures gain momentum, Japanese steel products may also be targeted and the export environment may worsen,' Maruyama continued. Meanwhile, analysts at BMO Capital Markets believe the sudden tariff hike could jolt domestic markets. 'The doubling of import tariffs, if maintained, is likely to create a panic in the market and trigger a restocking cycle that in our view has the potential to push prices >$1,000/st in the near-term,' the analysts said. However, they believe the spike would be temporary given macro uncertainty and seasonal demand trends. The broker upgraded Nucor (NYSE:NUE) to Outperform but downgraded Algoma Central (TSX:ALC), which it called 'a relative tariff loser.' The aluminum market may be more exposed, according to BMO. The U.S. covers only about 20% of its own aluminum consumption domestically, making it more vulnerable to supply disruptions. 'If tariffs do double, this is expected to put material upside pressure on the Midwest premium (MWP),' BMO wrote, estimating it could reach '$0.75/lb-plus' in theory, although higher aluminum cost will likely weigh on demand and thus offset some upside pressure. That said, the brokerage sees Century Aluminum (NASDAQ:CENX) as well positioned to benefit from a rise in the Midwest premium, while Alcoa (NYSE:AA) could see a negative impact of $1–2 per share, or 4–7%, due to its reliance on Canadian production. Still, BMO expects Alcoa may redirect some of its Canadian output to the EU market. Related articles Analysts assess the potential impact of Trump's surprise 50% steel tariffs Street Calls of the Week VIDEO: How to analyze a stock like a pro with the CEO of HF Foods
Yahoo
21 minutes ago
- Yahoo
1 Value Stock on Our Buy List and 2 to Approach with Caution
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues. Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored. Forward P/E Ratio: 14.5x Synonymous with "dad shoe", Skechers (NYSE:SKX) is a footwear company renowned for its comfortable, stylish, and affordable shoes for all ages. Why Is SKX Risky? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Estimated sales growth of 7.4% for the next 12 months implies demand will slow from its two-year trend Poor free cash flow margin of 4.4% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends Skechers is trading at $62.04 per share, or 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than SKX. Forward P/E Ratio: 9.9x Established in 1878, Mohawk Industries (NYSE:MHK) is a leading producer of floor-covering products for both residential and commercial applications. Why Are We Out on MHK? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth ROIC of 3.5% reflects management's challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned At $100.61 per share, Mohawk Industries trades at 9.9x forward P/E. Check out our free in-depth research report to learn more about why MHK doesn't pass our bar. Forward P/E Ratio: 3.7x Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Are We Bullish on SRPT? Annual revenue growth of 51.3% over the last two years was superb and indicates its market share increased during this cycle Earnings per share grew by 38.8% annually over the last five years, massively outpacing its peers Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business Sarepta Therapeutics's stock price of $37.50 implies a valuation ratio of 3.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Markel announces completion of MECO acquisition
LONDON, June 2, 2025 /CNW/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE:MKL), today announced that it has completed its acquisition of specialist marine MGA, The MECO Group Limited (MECO), following regulatory approvals. Andrew McMellin, President of Markel International, stated: "We're thrilled to finalise this acquisition and officially welcome MECO's people to Markel. MECO is a well-regarded brand, known for its professionalism, operational quality, and robust distribution channels in regions where we're actively expanding our presence. I look forward to the opportunities we can leverage as we join forces." Chris Else, Chief Executive of MECO, remarked: "This development represents an important milestone in the evolution of the MECO Group. Markel is a rapidly growing organisation that has built its success on a strong balance sheet, clear strategic vision, and philosophy of local empowerment. From early discussions with the leadership team, it was evident that their core values, as a people-powered business, make Markel an excellent fit for MECO as we embark on this new and exciting chapter." MECO, which has offices in London, Dubai, Shanghai and Hamburg, will trade as MECO Specialty, as part of the Specialty division of Markel International's Wholesale operation, led by Tom Hillier, Managing Director - Specialty. About Markel Insurance We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide. View original content to download multimedia: SOURCE Markel View original content to download multimedia:
